ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010

Also written as “MK-2010” and “LM-299”.

Its studies are mostly in Neoplasms · Ovarian Neoplasms, led by 2 companies.

Drug pageAnti-PD-1/Anti-VEGF Bispecific Antibody MK-2010: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 20, 20254 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only33 open or runningphase 2since Feb 20, 2025Feb 20, 2025Sep 26, 2028phase 2 · NCT07793942
Sino Biopharmaceuticalits history only11 open or runningphase 2since Oct 14, 2024Oct 14, 2024Dec 2026phase 2 · NCT06650566
  • Named in Merck’s own pipeline as MK-2010, phase 2, as of Nov 2, 2026 (source).

Also a collaborator on its studies: Daiichi Sankyo.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2024First study: phase 2 study in NeoplasmsNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06650566 · 108 planned · Australia, China
  2. Feb 20, 2025Merck’s first study: phase 2 study in Ovarian Cancer RecurrentNew to MerckMerck · NCT06843447 · 605 planned · United States, Australia, Canada and more
  3. Aug 21, 20262 phase 2 studiesMerck · NCT07785609, NCT07793942

Ahead

  1. Dec 2026Primary completion: phase 2 study in NeoplasmsSino Biopharmaceutical · NCT06650566
  2. Sep 26, 2028Primary completion: phase 2 study in Malignant NeoplamMerck · NCT07793942
  3. Mar 27, 2029Primary completion: phase 2 study in Ovarian Cancer RecurrentMerck · NCT06843447
  4. Sep 30, 2031Primary completion: phase 2 study in NeoplasmsMerck · NCT07785609

TargetBeta

“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon a…”NCIt, read by Claude
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
tivunatamigPfizerphase 315
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
ABBV-1480RemeGenphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039AruleMinghui Pharmaceuticalphase 23
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rulewigen-biomedicine-technology-shanghai-co-ltdphase 22
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rulecompass-therapeuticsphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07793942Malignant Neoplam · United States, Canada, Switzerland2RecruitingMerckSep 26, 2028480
NCT07785609Neoplasms · United States, Hong Kong, Switzerland2RecruitingMerckSep 30, 2031200
NCT06843447Ovarian Cancer Recurrent · United States, Australia, Canada and more2RecruitingMerckMar 27, 2029605
NCT06650566Neoplasms · Australia, China2RecruitingSino BiopharmaceuticalDec 2026108

How it is read

Names in the registry

  • “MK-2010”, 3 entries
  • “LM-299”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.